New hope for tough prostate cancer: targeted drug trial launches

NCT ID NCT06970119

First seen Jan 09, 2026 · Last updated May 14, 2026 · Updated 21 times

Summary

This study tests a new drug called INR102 in people with a specific type of advanced prostate cancer (PSMA-positive) that no longer responds to hormone therapy. The goal is to see if the drug is safe, how it moves through the body, and whether it can shrink tumors or lower PSA levels. About 55 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hospital of Jiangnan University

    NOT_YET_RECRUITING

    Wuxi, Jiangsu, 214000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tianjin Cancer Hospital Airport Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.